Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label dose-escalation study of psilocybin BTP23 in healthy adults
RBR-37qx63dPhase 1Not yet recruiting
- Sponsor
- Biocase Brasil
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin, sponsored by Biocase Brasil. Primary endpoints: Tolerability and Safety. Planned start May 2024; status: not yet recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on RBR-37qx63d.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-37qx63d.